Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.
Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).

This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).

Read More

Avance Clinical Invited to Present “Decentralized Trials – No Going Back” for Oracle Health Sciences Connect

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been invited to present on the future of decentralized clinical trials at the Oracle Health Sciences Connect conference.
Avance Clinical CEO Yvonne Lungershausen, shared the company’s insights on the future of Decentralized Clinical Trials (DCTs) and the technology and patient factors that will determine success.
Avance Clinical uses the full range of eClincial technologies to support clients wanting DCTs or a site-based approach while still leveraging advance technology including ePro, eSource and eConsent.

Read More

Avance Clinical Client Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa Therapeutics on the announcement of their Phase 1 final results for the AT-301 nasal spray being developed for COVID-19.

Read More

Avance Clinical Featured in Endpoints News

A year ago Australia was largely known predominantly for its early phase capabilities. However much has changed with Australia becoming the “COVID-19 free” envy of the world. Australia regularly records zero new daily COVID-19 cases, backed by the world’s leading contact tracing systems, mandatory travel quarantine, and strict borders.

Read More

COVID-19 and the APAC CRO Landscape | Avance Clinical featured in Biospectrum Asia

Australia has been recognized globally for its handling of the COVID-19 pandemic with strict quarantine systems and advanced contact tracing, resulting in low numbers of cases and deaths. Therefore we have seen a dramatic increase in the number of USA sponsors moving their trials to Australia.

Read More

News: Avance Clinical Adds Oracle Argus Safety and Pharmacovigilance Platform to its Clinical Technology Solutions

“We are excited to welcome Avance Clinical to our global community of Argus customers,” said Bruce Palsulich, Vice President, Safety Product Strategy, Oracle Health Sciences.

“Argus provides proven compliance with continuously changing worldwide regulations, and its built-in automations, integrations, and usability significantly reduce manual work and maximize efficiency. We are pleased that Avance Clinical has chosen to standardize on Argus for safety case management.”

Read More

AUSTRALIA & ASIA-PACIFIC CRO MARKET REPORT: Frost & Sullivan

Avance Clinical has positioned itself as a global leader in early phase clinical trials by developing innovative strategies and approaches to initial phase development. It helps global biotech companies set up clinic and achieve proof of concept faster with a data package that stands up to the scrutiny of global regulators. The company is well […]

Read More

ENDPOINTS NEWS: How Innovative Technologies and a Dedicated Site Network is Driving Patient Recruitment for Biotech Clinical Trials in Australia

Australia’s CRO for biotechs, Avance Clinical, deep dives into the patient recruitment landscape identifying the mechanisms and processes that deliver exceptional patient recruitment for early phase trials in Australia.

Read More

Client News: Avance Clinical Client Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

Avance Clinical is pleased to share the news that their client Atossa Therapeutics (NASDAQ: ATOS) has announced completion of enrollment in its Phase 1 clinical study.

Read More

Avance Clinical Wins MasterControl 2020 Innovation Excellence Award

The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.

Read More

Biotechs get scalable early to late phase clinical offering from Cromos Pharma and Avance Clinical collaboration in Australia and Europe

Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs.

Read More

News: Avance Clinical Client Atossa Therapeutics Announces Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that client Atossa Therapeutics has announced a positive interim safety assessment from the second cohort of healthy participants in the Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray.

Read More

News: Avance Clinical ‘ClinicReady’ Featured in Endpoints News

Avance Clinical has formed a dedicated scientific and regulatory affairs service, ClinicReady by Avance Clinical, in response to increased demand from biotechs for preclinical study management and scientific and regulatory advice to take their products to first-in-human trials.

The highly regarded Avance Clinical scientific and regulatory team, which has been advising biotech clients on their drug development for more than 20 years, is now a dedicated ClinicReady service under the Avance Clinical banner.

Read More

Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America

The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis.

Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)

Read More

News: Jorgen Mould PhD, BSc (Hons) joins Avance Clinical as Scientific Affairs Specialist

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to announce the appointment of Jorgen Mould PhD, BSc (Hons) as Scientific Affairs Specialist
Jorgen has over 23 years of experience in medical research and drug development.

With a passion for developing new treatments for human diseases, Jorgen has worked in positions that span the full spectrum of a drug lifecycle from bench side discovery to post market approval.

Read More

News: Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn’s disease.

Read More

Avance Clinical Client Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that Atossa Therapeutics have enrolled and dosed the first cohort of healthy participants in the Phase 1 clinical study using its proprietary drug candidate AT-301, being administered by nasal spray.

Read More

News | Mike Watson Appointed Avance Clinical Director, Business Development, USA

It is our pleasure to announce that Mike Watson has joined the Avance Clinical team as Director Business Development, USA.
Based in Raleigh North Carolina, Mike is a seasoned business development professional having spent the past 12 years in the clinical research space.

Read More

News | Avance Clinical Joins Medrio’s ‘Trial Talks’ Podcast about Why Clinical Trials are Thriving in Australia

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical, joins Medrio’s new podcast series Trial Talks. Trial Talks season 1, episode 1 “Why Clinical Trials are Thriving in Australia” focuses on how Avance Clinical prepared for the pandemic, what tools were leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.

Read More

News | Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa’s Second COVID-19 Therapeutic Development Program

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics’ proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa’s proprietary Endoxifen.

Read More

News | Avance Clinical Wins Frost & Sullivan “2020 Asia-Pacific CRO Market Leadership Award”

The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.

Read More

Avance Clinical Webinar & Podcast Series | Register here

Webinars CLICK HERE to Register for our Webinar Series on conducting clinical trials in Australia. Next: Early Phase Clinical Trials: Why taking the whole-of-health perspective is critical Date: 05th Aug 2020 Time: 01:30 PM (Singapore Time) We partner with leading biotech media companies such as Biospectrum Asia to share the latest on Australian clinical trials. Podcasts CLICK HERE to […]

Read More

Press Release: TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020

Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing.
Importantly in Australia, despite the global COVID-19 pandemic, no healthy volunteer studies have been suspended, and only 27 Phase 1 or 2 studies were temporarily put on hold for various reasons (TrialTrove, 9 June 2020).

Read More

Premier of South Australia Steven Marshall Briefed on $50 billion Clinical Trial Sector During Visit to Adelaide-based Avance Clinical

The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.

Read More

Endpoints News: About Avance Clinical’s Oncology Capabilities

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Read More

Webinar | Why biotechs are heading to Australia with Avance Clinical for their oncology trials

A joint BiospectrumAsia and Avance Clinical special webinar featuring Gabriel KremmidiotisPhD, BSC Hon, Chief Scientific Officer Avance Clinical. Registration is now open CLICK HERE

Read More

News Article | Avance reports 34% rise in clinical trials in Australia and New Zealand

Avance Clinical, which has been offering CRO services for more than two decades for early phase trials, reports 95 new trials were registered in the past 30 days as recorded in Australian and New Zealand registry ANZCTR.org.au Read the news article here

Read More

Press Release | Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis

Adelaide, Australia – Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time.   Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with […]

Read More

Avance Clinical on the Top Reasons APAC Biotech Clients Chose Australia for Clinical Trials

Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. Avance Clinical is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise. Avance Clinical said a primary reason that APAC biotechs chose Australia was […]

Read More

Video | About Avance Clinical COVID-19 capabilities

Read More

Avance Clinical Joins Industry Leaders at Conference Discussing The Future of Medicinal Cannabis

Read More

Soniclean Celebrates International Health – Business SA 2019 Export Awards

Read More